Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes

  • Judit Hodrea ,

    Contributed equally to this work with: Judit Hodrea, Adar Saeed

    Roles Formal analysis, Investigation, Writing – review & editing

    Affiliations MTA-SE “Lendület” Diabetes Research Group, Semmelweis University, Budapest, Hungary, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary

    ⨯
  • Adar Saeed ,

    Contributed equally to this work with: Judit Hodrea, Adar Saeed

    Roles Data curation, Investigation, Methodology

    Affiliations MTA-SE “Lendület” Diabetes Research Group, Semmelweis University, Budapest, Hungary, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary

    ⨯
  • Agnes Molnar,

    Roles Data curation, Formal analysis

    Affiliations MTA-SE “Lendület” Diabetes Research Group, Semmelweis University, Budapest, Hungary, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary

    ⨯
  • Attila Fintha,

    Roles Investigation, Methodology, Validation

    Affiliation 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

    ⨯
  • Adrienn Barczi,

    Roles Data curation, Formal analysis, Investigation, Methodology

    Affiliation MTA-SE “Lendület” Diabetes Research Group, Semmelweis University, Budapest, Hungary

    ⨯
  • Laszlo J. Wagner,

    Roles Conceptualization, Supervision, Writing – review & editing

    Affiliation Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary

    ⨯
  • Attila J. Szabo,

    Roles Supervision

    Affiliations 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary, ELKH-SE Pediatrics and Nephrology Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary

    ⨯
  • Andrea Fekete,

    Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing

    Affiliations MTA-SE “Lendület” Diabetes Research Group, Semmelweis University, Budapest, Hungary, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary

    ⨯
  • Dora B. Balogh

    Roles Conceptualization, Methodology, Project administration, Writing – original draft

    dorabiankabalogh@gmail.com

    Affiliations MTA-SE “Lendület” Diabetes Research Group, Semmelweis University, Budapest, Hungary, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary

    ⨯

Abstract

Introduction

Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reduction in the relative risk of heart failure by sodium-glucose cotransporter 2 inhibitors (SGLT2i) are partly beyond their glucose lowering effects, however, the molecular mechanisms are still elusive. Here we investigated the role of SGLT2i dapagliflozin (DAPA) in the prevention of diabetes-induced cardiovascular complications.

Methods

Type 1 diabetes was induced with streptozotocin (65 mg/bwkg, ip.) in adult, male Wistar rats. Following the onset of diabetes rats were treated for six weeks with DAPA (1 mg/bwkg/day, po.).

Results

DAPA decreased blood glucose levels (D: 37±2.7 vs. D+DAPA: 18±5.6 mmol/L; p<0.05) and prevented metabolic decline. Aortic intima-media thickening was mitigated by DAPA. DAPA abolished cardiac hypertrophy, and myocardial damage. Cardiac inflammation and fibrosis were also moderated after DAPA treatment.

Conclusions

These data support the preventive and protective role of SGLT2i in diabetes-associated cardiovascular disease. SGLT2i may provide novel therapeutic strategy to hinder the development of cardiovascular diseases in type 1 diabetes, thereby improve the outcomes.

Citation: Hodrea J, Saeed A, Molnar A, Fintha A, Barczi A, Wagner LJ, et al. (2022) SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PLoS ONE 17(2): e0263285. https://doi.org/10.1371/journal.pone.0263285

Editor: Zhongjian Cheng, Temple University, UNITED STATES

Received: July 16, 2021; Accepted: January 17, 2022; Published: February 17, 2022

Copyright: © 2022 Hodrea et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting Information files.

Funding: Funding for this study was provided by National Research, Development and Innovation Office (FK-124491, 2017-1.3.1-VKE-2017-00006), Thematic Excellence Program (2020-4.1.1.-TKP2020) of the Ministry for Innovation and Technology in Hungary, within the framework of the 6183169273 thematic program, and the 6183069269 institutional excellence program of the Semmelweis University, and Ministry for Innovation and Technology (UNKP-19-3-III-SE-6), Lendulet LP2021-3/2021.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: α-SMA, Alpha-Smooth Muscle Actin; ANP, Atrial Natriuretic Peptide; BNP, B-Type Natriuretic Peptide; CTGF, Connective Tissue Growth Factor; cTn, Cardiac Troponins; cTnI, Cardiac Troponin I; cTnT, Cardiac Troponin T; CVD, Cardiovascular Disease; DAPA, Dapagliflozin; DCM, Diabetic Cardiomyopathy; DM, Diabetes Mellitus; ECM, Extracellular Matrix; FDA, Food and Drug Administration; FGF, Fibroblast growth factor; FN, Fibronectin; HF, Heart Failure; IL-1β, Interleukin-1β; IL-6, Interleukin-6; IMT, Intima-Media Thickness; LV, Left Ventricular; MAP, Mean Arterial Pressure; MCP-1, Monocyte Chemoattractant Protein 1; Nlrp3/ASC, (NOD) like receptor protein 3/ apoptosis-associated speck; PAI-1, Plasminogen Activator Inhibitor 1; PDGF, Platelet-Derived Growth Factor; Rn18S, 18S Ribosomal RNA; SGLT2i, Sodium-Glucose Cotransporter 2 Inhibitors; STZ, Streptozotocin; T1DM, Type 1 Diabetes Mellitus; T2DM, Type 2 Diabetes Mellitus; TGF-β, Transforming Growth Factor Beta; TNF-α, Tumor Necrosis Factor Alpha

Introduction

Cardiovascular disease (CVD) and related mortality are increasing at an alarming rate, also as a consequence of growing prevalence of diabetes mellitus (DM) [1]. About two-thirds of deaths in people with diabetes are due to CVD including mainly ischemic heart disease, but also congestive heart failure (HF) and stroke [2]. The impact of type 1 DM (T1DM) and type 2 DM (T2DM) on CVD mortality is similar, however T1DM patients are younger at the onset of the disease, thus they lose more life-years due to CVD [3, 4]. Impaired glucose metabolism, inflammation, and cell signaling abnormalities lead to premature atherosclerosis, myocardial remodeling, and left ventricular (LV) fibrosis contributing to cardiovascular damage. So far, commonly applied glucose-lowering agents have had little or no impact on CVD progression and outcomes in diabetic patients. Therefore, identifying novel therapeutic strategies targeting cardiovascular inflammation and fibrosis is of paramount importance in the management of CVD especially in T1DM.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a novel class of antidiabetic drugs mainly used in T2DM. To date, dapagliflozin (DAPA) is the only approved selective SGLT2i in adults with T1DM in the European Union. Considerable advantage of SGLT2i is that they work independently of insulin by blocking proximal tubular glucose reabsorption resulting in reduced plasma glucose level and glucosuria. Large-scale clinical trials: EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58 [5–7] have been evaluated the selective SGLT2i empagliflozin, canagliflozin, and DAPA for their cardiovascular safety. Each of these trials were associated with reduction in the relative risk of HF indicating a class effect of SGLT2i. Moreover, the DAPA-HF study reported that DAPA was more efficient compared to placebo in the prevention of cardiovascular death and HF, regardless of the presence or absence of DM [8]. Further, based on the DAPA-HF trial the US Food and Drug Administration (FDA) has recently approved DAPA to reduce the risk of cardiovascular death in adults with heart failure with reduced ejection fraction [9]. These data suggest that the cardioprotective effects of SGLT2i cannot be solely attributed to the glucose lowering action.

Elevated levels of inflammatory mediators are associated with hyperglycemia, insulin resistance, and may predict the development of DM [10]. Growing body of evidence revealed that chronic inflammation is a major driver of diabetic cardiomyopathy (DCM) [11, 12]. Accordingly, inflammation could be a possible common mechanism in the pathophysiology of both DM and CVD. Glucotoxicity and dyslipidemia directly induce upregulation and secretion of inflammatory mediators and contribute to atherosclerosis, cardiac hypertrophy, remodeling, fibrosis and may interfere with cardiomyocyte contractile properties [13]. Recent studies demonstrated that empagliflozin and DAPA reduce cardiac interstitial macrophage infiltration in prediabetic rats and in infarcted rat hearts, decrease mRNA expressions of interleukin-1β (IL-1β), interleukin-6 (IL-6) and mitigate the activation of Nlrp3/ASC inflammasome, thus attenuate the development of DCM in T2DM mouse model [14–16]. However, literary data is scanty about the anti-inflammatory role of SGLT2i in T1DM.

Bearing in mind the high relative risk of death from CVD in T1DM and the enormous importance of SGLT2i as possible cardioprotective agents in T2DM, it is important to investigate whether DAPA can mitigate the development of DCM in T1DM. In the present study, DAPA was applied to test its anti-inflammatory properties in the prevention of atherosclerosis and cardiac fibrosis in a streptozotocin-induced T1DM rat model.

Materials and methods

Study approval

All experiments were conducted in accordance with guidelines of the Committee on the Care and Use of Laboratory Animals of the Semmelweis University Budapest, Hungary (PEI/001/1731-9-2015).

Materials

All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), and all standard plastic laboratory equipment was purchased from Sarstedt (Numbrecht, Germany) unless otherwise stated.

Animals and study design

Experiments were performed on eight-week-old male Wistar rats (Rattus norvegicus) purchased from Toxi-Coop (Budapest, Hungary). Rats were placed in groups of three per cage under controlled light and temperature (12:12 hour light-dark cycle at 24±2°C) with ad libitum access to standard rodent diet and tap water. Rats underwent an acclimatization period for one-week before the commencement of the experiment. The health and well-being of the animals were monitored daily by a qualified person. Refined aspects of housing, husbandry, enrichment, and socialization were applied to prevent or alleviate distress (the number of the animals used for the experiment was reduced to the absolute minimum necessary, harming ambient light, noise, vibrations, fluctuations or extremes in temperature were absent; environment enrichment and more frequent, gentle and predictable handling were applied; husbandry handling was combined with habituation and handling for research purposes).

T1DM was chemically induced with a single intraperitoneal injection of 65 mg/bwkg streptozotocin (STZ) dissolved in 0.1 M citrate buffer (pH 4.5) after overnight fasting. Blood glucose levels were measured three times from tail vein with a D-Cont Ideal device (77 Elektronika, Budapest, Hungary). Rats with a peripheral blood glucose value above 15 mmol/L 72 hours after the STZ injection were enrolled in the study. Diabetic (D) rats were randomly divided into two groups immediately after the onset of diabetes (n = 6/groups) and were treated per os as follows: (i) isotonic saline (NaCl 154 mmol/L) as vehicle (D) and (ii) DAPA dissolved in isotonic saline (D+DAPA; 1 mg/bwkg/day). Age-matched non-diabetic controls (C) received the equivalent volume of citrate buffer without STZ once, and the same amount of saline by oral gavage daily at the same time as the diabetic animals during the six-week study period (n = 6 /group). To prove the safety of the treatment, an additional DAPA-treated non-diabetic control group (C+DAPA, 1 mg/bwkg/day) was investigated only for laboratory parameters. These results are presented as Supporting Information. Blood pressure, serum and urinary parameters were determined at the end of the study period. Rats were placed into metabolic cages to collect urine for a 24-hour period before euthanasia. At the end of the protocol rats were euthanised using a mixture of 75 mg/bwkg ketamine (Richter Gedeon, Budapest, Hungary) and 10 mg/bwkg xylazine (Medicus Partner, Biatorbagy, Hungary).Blood, urine, and tissue samples were collected, weighed, and stored for further investigations.

Measurement of arterial blood pressure

A CODA tail-cuff standard monitoring system (EMKA Technologies, Paris, France) was used to measure the systolic and diastolic blood pressures, which is based on volume pressures recording and is a clinically validated technology. Mean arterial pressure (MAP) was calculated. The recording was performed in a suitable environment without any distractions. Rats were adapted for 10 min/day to the measurement in 2 days before the recording started. Subsequently, rats stayed quiet and remained in the holder on the testing day.

Measurement of metabolic parameters

Serum and urine samples were measured with available standard kits on a Hitachi 912 photometric chemistry analyzer (Roche Hitachi, Basel, Switzerland). Glucosuria was determined from 24-hour collected urine.

Measurement of klotho and cardiac troponin I

Serum klotho and cardiac troponin I were measured according to the manufacturer’s protocol using Rat Klotho ELISA Kit (ABclonal, Woburn, MA, USA) and Rat Cardiac Troponin I ELISA Kit (Abcam, Cambridge, UK). 96-well microplates were analyzed with SPECTROstar Nano microplate reader (BMG Labtech, Ortenberg, Germany) at 450 nm with 650 nm as reference.

Histology

Amount of elastic fibers were investigated on orcein stained aorta sections. The aorta was dissected under a light microscope, immediately fixed in 8% paraformaldehyde, and embedded in paraffin for immunohistochemistry. 5 μm sections were deparaffinized in xylene and rehydrated (100%, 90%, 70% ethanol, and distilled water). Sections were immersed in 1% orcein at 60°C for 30 min, followed by differentiation in acid-alcohol (1:99 hydrochloric acid and 70% ethanol) for 10 seconds to remove the dye excess, and then into distilled water. Histological examination was performed under 20x objective magnification using Case Viewer 2.4. (3DHISTECH, Budapest, Hungary). Intima-media thickness (IMT) was measured on cross sections of the aorta and the mean value of ten measurements were calculated.

Collagen content and perivascular fibrosis of the left ventricle was determined with picrosirius red staining. Fresh frozen heart tissues were sectioned with 4 μm thickness, slides were stained, and were digitalized with a Pannoramic1000 slide scanner (3DHistech, Budapest, Hungary). The slides were visualized with SlideViewer2.5 (3DHistech, Budapest, Hungary), and intramyocardial collagen represented red-colored area was measured with the Quant Center HistoQuant 2.5 module (3DHistech, Budapest, Hungary). The myocardial field of measurement was manually selected with the caution of avoiding the endocardium and perivascular connective tissue. The surface of measurement was 1,6 mm2 in each heart. The red-stained area was measured based on the red color intensity. First, multiple optimalization measurements were performed with the supervision of an experienced cardiovascular histopathologist, reaching the best RGB pixel intensity parameters: Red channel 84–221, Green channel 8–142, Blue channel 10–137. Then the red-stained area measurements were performed on each histological slide.

Quantitative RT-PCR

Total RNA was extracted using the Total RNA Mini Kit (Geneaid Biotech, New Taipei City, Taiwan). Measurement of quality and quantity of isolated RNA was performed by NanoDrop ND-1000 spectrophotometer (Baylor College of Medicine, Houston, TX, USA). RNA (500 ng) was reverse-transcribed using the Maxima™ First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific, Waltham, MA, USA) to generate first-strand cDNA. Atrial natriuretic peptide (Nppa), B-type natriuretic peptide (Nppb), transforming growth factor beta (Tgfb1), platelet-derived growth factor (Pdgfb), connective tissue growth factor (Ccn2), plasminogen activator inhibitor 1 (Serpine1), fibronectin (Fn), interleukin-1β (Il1b), interleukin-6 (Il6), tumor necrosis factor alpha (Tnf), monocyte chemoattractant protein 1 (Ccl2), and 18S ribosomal RNA (Rn18S) were determined by using LightCycler 480 SYBR Green I Master enzyme mix (Roche Diagnostics, Indianapolis, IN, USA) and specific primers listed in Table 1. Results were analyzed by LightCycler® 480 software (version 1.5.0.39, Roche Diagnostics). Target gene expressions were normalized against Rn18S as a housekeeping gene.

thumbnail
Download:
Table 1. Sequences of primer pairs for quantitative RT-PCR.

https://doi.org/10.1371/journal.pone.0263285.t001

Western blot analysis

All chemicals and reagents for Western blot analysis were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Total protein was extracted from the left ventricle of the heart. Samples were homogenized in lysis buffer by TissueLyser LT homogenisator (Qiagen, Hilden, Germany). Protein concentrations were measured and mixed with 4x Laemmli sample buffer (1:3) and heated at 95°C for 5 minutes. Appropriate amount of proteins were electrophoretically resolved on polyacrylamide gradient gels (4–20%), then transferred to nitrocellulose membranes. The protein transfer was verified by 1% Ponceau S staining. After blocking, membranes were immunoblotted with specific primary antibody: α-SMA (A2547; Sigma Aldrich; 1:500). After repeated washing, the blots were incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies. LuminataTM Forte Western HRP Substrate (Millipore Corporation, Billerica, MA, USA) was used for chemiluminescent detection of blots. Densitometric analysis of bands was performed by Quantity One Analysis software (Bio-Rad Laboratories). After background subtraction, integrated optical densities of bands of interest were factored for Ponceau S staining to correct for variations in total protein loading. Each blot was normalized to an internal control so that bands on separate blots could be compared.

Statistical analysis

Data are expressed as means±standard deviations (SD). Statistical analysis was performed using Prism software (version 7.0; GraphPad Software, San Diego, CA, USA). Multiple comparisons and interactions were evaluated by one-way ANOVA followed by Holm-Sidak post hoc test. For non-parametrical data, the Kruskal-Wallis ANOVA on ranks followed by with Dunn’s correction was used. P values of <0.05 were considered significant.

Results

DAPA prevents metabolic decline in diabetic rats

Typical metabolic features of DM such as weight loss, elevated serum glucose, fructosamine, and lipid levels developed after 6 weeks of T1DM. As expected, DAPA markedly improved all metabolic parameters, while had no effect in non-diabetic control rats except inducing glucosuria (S1 Table). Dysregulation of carbohydrate metabolism was ameliorated in DAPA-treated diabetic rats, which was confirmed by the decrement of serum glucose and fructosamine levels. In parallel, DAPA enhanced the urinary glucose excretion in both control and diabetic groups confirming the mechanism of action of SGLT2i. Diabetes-induced dyslipidemia was normalized to control levels in DAPA-treated rats (Table 2).

thumbnail
Download:
Table 2. Dapagliflozin treatment improves T1DM-induced metabolic changes.

https://doi.org/10.1371/journal.pone.0263285.t002

Cardiac hypertrophy and reduction in heart rate are hindered by DAPA

Systolic and diastolic pressure and heart rate were measured, mean arterial pressure (MAP) was calculated. After six weeks of DM, MAP remained unaltered in all groups. In line with the literature and other previous studies, STZ-induced DM was associated with reduction in heart rate [17, 18], which was reversed by DAPA treatment.

Cardiac hypertrophy developed in diabetic rats as indicated by increased heart to body weight ratio. DAPA treatment prevented cardiac hypertrophy (Table 3). Since all investigated parameter were the same in DAPA-treated non-diabetic controls (S1 and S2 Tables), further molecular research was performed only in control, diabetic and DAPA-treated diabetic rats.

thumbnail
Download:
Table 3. Mean arterial pressure, heart rate and heart to body weight ratio.

https://doi.org/10.1371/journal.pone.0263285.t003

Intima-media thickening is prevented by DAPA

Aortic IMT is an early marker of atherosclerosis. Changes in aortic IMT occur at early stages of the progression of T1DM and these become more severe with the duration of the disease [19, 20]. Histological examination of aortic IMT showed prominent wavy internal elastic lamina in control rats. Aorta of diabetic rats showed intimal thickening, irregularity and diffused elastic membranes, which was prevented by DAPA (Fig 1).

thumbnail
Download:
Fig 1. Intima-media thickening is prevented by dapagliflozin.

Representative orcein stained aorta sections and quantitative evaluation of intima-media thickness (IMT) of control, diabetic (D) and dapagliflozin treated diabetic rats (D+DAPA). Original magnification, x200. Scale bar, 50 μm. Elastic fibers are stained brown after orcein staining. They are visualized as either thin fibers or elastic lamella. Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n = 6/group). *p<0.05 vs. Control, §p<0.05 vs. Diabetic.

https://doi.org/10.1371/journal.pone.0263285.g001

DAPA mitigates the elevation of specific biomarkers of myocardial injury

Atrial natriuretic peptid (ANP) is considered as a marker for myocardial hypertrophy. It is mainly produced in the atria, but it is present in the ventricles as well. B-type natriuretic peptid (BNP) has been proposed as a useful biomarker for the determination of acute and chronic LV dysfunction, thus HF. BNP is predominantly released in response to LV volume expansion and pressure overload [21]. Therefore, mRNA expressions of Nppa (ANP) and Nppb (BNP) were measured in the LV. Nppa and Nppb were robustly elevated in the left ventricle of diabetic rats. Levels of both Nppa and Nppb were less elevated in DAPA-treated group (Fig 2A and 2B).

thumbnail
Download:
Fig 2. Diabetes-induced myocardial injury biomarker increment is halted by dapagliflozin.

mRNA expression of (A) atrial natriuretic peptide (Nppa) and (B) B-type natriuretic peptide (Nppb) of control, diabetic and dapagliflozin treated diabetic rats (D+DAPA). mRNA expressions were normalized to Rn18S mRNA expression. (C) Serum levels of cardiac troponin I. (D) Serum levels of klotho. Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test or Kruskal-Wallis with Dunn comparison test (n = 6/group). *p<0.05 vs. Control, **p<0.01 vs. Control, ***p<0.001 vs. Control, §p<0.05 vs. Diabetic, §§§p<0.001 vs. Diabetic.

https://doi.org/10.1371/journal.pone.0263285.g002

Cardiac troponins (cTn) received international approval as myocardial injury biomarker [22]. cTnI regulatory protein controls calcium-mediated interaction between actin and myosin and is a clinical indicator of myocardial cell damage [23]. Here we showed that DM-induced serum level of cTnI was decreased in DAPA-treated group (Fig 2C).

Klotho is a putative anti-aging protein, and it forms a unique endocrine system that regulates multiple metabolic processes (e.g., oxidative stress, inflammation, fibrosis). Here we found that klotho was downregulated in the serum of T1DM rats, which was halted by DAPA treatment (Fig 2D).

Diabetes-induced cardiac inflammation is diminished by DAPA treatment

Chronic inflammation has been implicated in the pathogenesis of DCM. Cardiac overexpression of TNF-α, and IL-6 has been associated with myocardial damage, hypertrophy and fibrosis, as well with LV dysfunction. Accordingly, to investigate the anti-inflammatory properties of DAPA, Il1b, Il6, Tnf and Ccl2 (MCP-1) mRNA expressions were measured in the left ventricle. All investigated cytokines and chemokine expressions were elevated in diabetic rats. Here we showed that DM-induced Il1b, Il6 and Tnf increment were abolished in DAPA treated group suggesting less severe inflammation induced myocardial damage (Fig 3A–3D).

thumbnail
Download:
Fig 3. Dapagliflozin mitigates pro-inflammatory response in diabetic heart rats.

mRNA expression of (A) interleukin-1β (Il1b), (B) interleukin-6 (Il6), (C) tumor necrosis factor (Tnf), and (D) monocyte chemoattractant protein 1 (Ccl2) of control, diabetic and dapagliflozin treated diabetic rats (D+DAPA). mRNA expressions were normalized to Rn18S mRNA expression. Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n = 6/group) *p<0.05 vs. Control, **p<0.01 vs. Control, ***p<0.001 vs. Control, §p<0.05 vs. Diabetic, §§p<0.01 vs. Diabetic.

https://doi.org/10.1371/journal.pone.0263285.g003

Progression of myocardial fibrosis is suspended in DAPA-treated diabetic rats

In murine models, STZ-induced DM is associated with induction of pro-fibrotic genes and interstitial cardiac fibrosis. Therefore, to evaluate the role of DAPA in the prevention of cardiac fibrosis, profibrotic markers Tgfb1, Pdgfb, Ccn2 (CTGF) and Serpine1 (PAI-1) mRNA expressions were determined. Diabetic rats had an increased LV mRNA expression of aforementioned profibrotic markers. DAPA treatment diminished the elevation of Tgfb1, Ctgf and Serpine1 (Fig 4A–4D). In parallel, myofibroblast marker α-SMA protein levels were upregulated in the diabetic group, which was lowered by DAPA (Fig 4E). Extracellular matrix (ECM) component fibronectin has a pivotal role in myocardial remodeling responses to pathological injury. DM-induced higher Fn expression was suspended by DAPA indicating milder myocardial remodeling and fibrogenesis (Fig 4F).

thumbnail
Download:
Fig 4. Dapagliflozin attenuates fibrosis in the left ventriculum of diabetic rats.

mRNA expression of (A) transforming growth factor β (Tgfb1), (B) platelet-derived growth factor (Pdgfb), and (C) connective tissue growth factor (Ccn2) of control, diabetic and dapagliflozin treated diabetic rats (D+DAPA). (D) mRNA expression of Serpine1 (also known as plasminogen activator inhibitor-1). (E) Protein level of α-smooth muscle actin (α-SMA). Proteins were normalized to total protein Ponceau S staining as loading control. (F) mRNA expression of fibronectin (Fn). mRNA expressions were normalized to Rn18S mRNA expression. Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n = 6/group) *p<0.05 vs. Control, **p<0.01 vs. Control, ***p<0.001 vs. Control, §p<0.05 vs. Diabetic, §§p<0.01 vs. Diabetic, §§§p<0.001 vs. Diabetic.

https://doi.org/10.1371/journal.pone.0263285.g004

Myocardial collagen content and perivascular fibrosis of the left ventricle was studied with picrosirius red staining. Diabetes-induced intramyocardial collagen deposition was detected. Collagen accumulation was reduced almost to control levels in the DAPA-treated group confirming its protective role and efficiency in decreasing cardiac fibrosis (Fig 5).

thumbnail
Download:
Fig 5. Diabetes-induced cardiac fibrosis is mitigated by DAPA treatment.

Representative picrosirius red stained heart sections and quantitative evaluation of fibrosis of Control, diabetic (D) and dapagliflozin treated diabetic rats (D+DAPA). The red-stained area was measured based on the red color intensity. The myocardial field of measurement was manually selected with the caution of avoiding the endocardium and perivascular connective tissue. Original magnification, x400. Scale bar, 50 μm. Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n = 5-6/group). *p<0.05 vs. Control, §p<0.05 vs. Diabetic.

https://doi.org/10.1371/journal.pone.0263285.g005

Discussion

T1DM is associated with premature CVD and an increased risk of cardiovascular mortality [24]. Remodeling in the left ventricle is frequently observed in patients with T1DM and refers to structural changes associated with increased volume, myocyte hypertrophy, myofibroblast proliferation, and interstitial fibrosis. Thus, reversing or even preventing LV remodeling is an important target in the prevention of DCM. Our study provides experimental evidence that oral administration of SGLT2i DAPA over a 6-week period prevents metabolic decline, cardiac hypertrophy, and myocardial injury in STZ-induced T1DM. Reduction in aortic IMT suggests that DAPA could also prevent atherosclerosis. We also revealed that DAPA decreases the gene expressions related to LV hypertrophy, myocardial dysfunction, inflammation, and fibrosis indicating that DAPA alters the cardiac remodeling in diabetic rats.

The proof of cardiovascular safety for new glucose-lowering therapies has been required by US FDA since 2008. SGLT2i are a new class of antidiabetic medications showing reduction in the relative risk of HF in T2DM, as recently proven in EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58, respectively [5–7]. The beneficial effects in cardiovascular outcome and mortality were also present in non-diabetic HF patients undergoing DAPA treatment [8]. SGLT2i reduce blood pressure, decrease body weight or induce natriuresis suggesting that consistent cardioprotection does not only relate to their antihyperglycemic action. Despite the encouraging results of these trials, the underlying molecular mechanisms of cardioprotection remain incompletely understood. Furthermore, the literary data is scarce about the effect of SGLT2i in T1DM.

Premature atherosclerosis is the main cause of mortality in T1DM with cardiovascular events occurring more than a decade earlier. Atherosclerosis begins early in life, but usually becomes symptomatic in adulthood. The build-up of fats, cholesterol, calcium in the arterial wall lead to arterial wall thickening and the development of arterial plaques [25]. Therefore, the prevention of atherosclerosis can be a crucial factor to reduce the risk of CVD later in life. Since earliest changes in vascular structure occur first in the abdominal aorta and IMT is an early marker of atherosclerosis, we measured aortic IMT of rats [26, 27]. Aorta of diabetic rats showed intimal thickening, irregularity and diffused elastic membranes, which were prevented by DAPA in T1DM. Only two non-randomized and one randomized studies evaluated the effects of SGLT2i on carotid IMT in T2DM patients. Empagliflozin reduced IMT, while ipragliflozin and tofogliflozin had no statistically significant alterations in IMT [28–30]. However, these studies have limitations: having small sample size and short treatment duration or not being a double-blind, placebo-controlled trial. A recent study reported that low serum klotho level is associated with larger thickness of carotid artery intima-media, thus it may be considered as an early predictor of atherosclerosis [31]. Here we found that DAPA reversed the decrement of serum klotho in T1DM. In parallel, in our study DM-induced serum total cholesterol-, triglyceride-, and LDL-C elevation were normalized to control levels in DAPA-treated rats, similarly to what was recently reported in T2DM murine models [32, 33]. According to this, SGLT2i may prevent atherosclerosis, however further investigations are needed to clarify the effects of SGLT2i on IMT.

Natriuretic peptides are predominantly produced in the atria and ventricles in response to increased cardiac stretch, thus they are powerful predictors of ventricular dysfunction and cardiovascular outcomes. Elevated ANP expression in adult ventricles is a marker for the development of hypertrophy, while BNP is predominantly released in response to LV volume expansion and pressure overload [34]. Levels of ANP and BNP are increased in diabetic patients, prediabetic and T2DM rat models [35–38]. Here, both natriuretic peptides were robustly elevated in the left ventricle of T1DM rats verifying LV dysfunction. Both Nppa and Nppb were less increased in DAPA-treated group, similar to what was recently observed in patients with T2DM [39, 40]. cTn are components of the contractile apparatus of myocardial cells and are accepted as standard biomarker for the diagnosis and prediction of myocardial injury [41]. cTnI is also elevated in HF patients with DM [42]. Canagliflozin possesses favorable effects on high‐sensitivity cTnI reduction in patients with T2DM [43]. Similarly, elevation of serum cTnI was observed in our T1DM experiment model, which was decreased by DAPA. Treatment with DAPA delayed the elevation of hypertrophy and myocyte damage markers indicating that SGLT2i may play a protective role in T1DM-induced ventricular remodeling.

Klotho proteins have received a great attention in the past few years as possible sensitive and specific markers for chronic kidney disease and CVD. Klotho proteins form a unique endocrine system that regulates multiple metabolic processes such as inactivation of oxidative stress, inflammation, and fibrotic pathways in the heart, cardiomyocytes, and kidney [44–46]. Recent studies reported that klotho level is lower in patients with T2DM and CVD supporting its protective role in DM-related cardiorenal diseases [47, 48]. The effect of SGLT2i on klotho in the serum has not been reported to-date, moreover only one study examined their connection in the kidney. Our finding demonstrates that DAPA halts the decrement of serum klotho in T1DM. Empagliflozin increased renal klotho expression in unilateral ureteric obstruction rat model [49]. Based on these findings, SGLT2i improve klotho levels independent of DM suggesting a novel mechanism of action in cardiorenal protection.

The link between the pathophysiology of DM and CVD is complex and multifactorial [50]. Inflammation has been implicated in the pathophysiology of both diseases. According to the ‘cytokine hypothesis’ HF is partly a consequence of activated endogenous cytokine cascades in the heart and circulation [51]. Pro-inflammatory cytokines (e.g. TNF-α, IL-1β) cause cardiac myocyte hypertrophy, contractile dysfunction, LV dilatation and modulate the interstitial matrix of the heart [52, 53]. Increased serum TNF-α and IL-6 levels of diabetic patients are associated with LV diastolic dysfunction [54]. In our experiment, elevation of Il1b, Il6, Tnf and Ccl2 in the left ventricle indicate the activation of inflammatory signaling pathways, similarly to other T1DM models [55, 56]. We showed that DM-induced cardiac inflammation is diminished by DAPA treatment. This is in line with the anti-inflammatory effect of empagliflozin and DAPA observed in T2DM rodent models [16, 57]. Moreover, SGLT2i attenuated inflammation in infarcted rat hearts of APOE knockout mice and LPS mice model suggesting that cardioprotection does not solely depend on glucose lowering actions [15, 58, 59]. Together with literary data, our findings support the anti-inflammatory role of SGLT2i as a possible mechanism of action in the prevention of CVD.

Cardiac fibrosis is the common final pathway through which HF develops. Clinical studies showed the presence of myocardial fibrosis in patients with DM, which may occurs independently of hypertension or coronary atherosclerosis [60, 61]. Hyperglycemia-induced cardiac fibrosis provokes pathological changes that culminate in activation of TGF-β pathway and deposition of ECM proteins leading to increased myocardial stiffness and impaired cardiac function [62]. Recent studies showed that SGLT2i attenuate cardiac fibrosis in T2DM rodent models and TGF-β-induced fibroblast activation in human cardiac fibroblasts [63–65]. We previously reported that DAPA has antifibrotic effects in T1DM kidneys, therefore it seemed plausible that DAPA prevents fibrosis in the heart as well [66]. Here we found that elevated Tgfb1, and Ccn2 expressions were reduced in DAPA-treated rats. Further, we showed that accumulation of α-SMA, Fn and collagen were also mitigated after DAPA treatment supporting the antifibrotic potential of SGLT2i. These results suggest that SGLT2 inhibition, independent of the type of DM, may have propitious effects on cardiac TGF-β pathway, thus myocardial fibrosis.

In conclusion, the current study provides experimental data for the cardioprotective effect of DAPA in experimental T1DM. Our results indicate that DAPA prevents intimal thickening, cardiac inflammation, and fibrosis. All these mechanisms suggest that a complex system lies behind the organoprotective effect of SGLT2i. Ultimately, various SGLT2i may provide a novel therapeutic opportunity to treat and improve outcomes of DM and related disorders simultaneously.

Study limitation

Cardiovascular function (e.g., hemodynamics, echocardiography) measurements were not performed during the animal experiment due to the lack of equipment in our laboratory.

Supporting information

S1 Table. Dapagliflozin treatment did not affect control animals.

Metabolic parameters of control, dapagliflozin-treated control (C+DAPA) rats at the end of the 6-week experimental period. Values are presented as means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n = 6/group). **p<0.01 vs. Control. UN: undetectable, LDL-C: low-density lipoprotein cholesterol, GOT: serum glutamate-oxaloacetate transaminase, GPT: serum glutamate-pyruvate transaminase.

https://doi.org/10.1371/journal.pone.0263285.s001

(PDF)

S2 Table. Mean arterial pressure, heart rate and heart to body weight ratio.

Mean arterial pressure, heart rate and heart to body weight ratio of control, dapagliflozin-treated control (C+DAPA) rats. Values are presented as means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test or Kruskal-Wallis with Dunn comparison test (n = 6/group).

https://doi.org/10.1371/journal.pone.0263285.s002

(PDF)

S1 Data.

https://doi.org/10.1371/journal.pone.0263285.s003

(PDF)

Acknowledgments

The authors are grateful to Adam Hosszu, Lilla Lenart, Maria Bernath and Iren Szabo who provided excellent technical assistance.

References

  1. 1. Collaborators GCD. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in;195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (vol 392, pg 1736, 2018). Lancet. 2018;392(10160):2170.
  2. 2. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus—Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133(24):2459–502. pmid:27297342
  3. 3. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008;31(4):714–9. pmid:18083789
  4. 4. Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140–6. pmid:21705065
  5. 5. Wanner C, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(18):1801–2. pmid:27806236
  6. 6. Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. pmid:29166232
  7. 7. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–57. pmid:30415602
  8. 8. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008. pmid:31535829
  9. 9. Raj GM, Wyawahare M. Dapagliflozin for heart failure—is it a class effect? Future Cardiol. 2020. pmid:32755319
  10. 10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34. pmid:11466099
  11. 11. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–19. pmid:16778830
  12. 12. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116(7):1254–68. pmid:25814686
  13. 13. Frati G, Schirone L, Chimenti I, Yee D, Biondi-Zoccai G, Volpe M, et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res. 2017;113(4):378–88. pmid:28395009
  14. 14. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157. pmid:27835975
  15. 15. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310. pmid:28132924
  16. 16. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119–32. pmid:28447181
  17. 17. Schaan BD, Maeda CY, Timm HB, Medeiros S, Moraes RS, Ferlin E, et al. Time course of changes in heart rate and blood pressure variability in streptozotocin-induced diabetic rats treated with insulin. Braz J Med Biol Res. 1997;30(9):1081–6. pmid:9458968
  18. 18. Hicks KK, Seifen E, Stimers JR, Kennedy RH. Effects of streptozotocin-induced diabetes on heart rate, blood pressure and cardiac autonomic nervous control. J Auton Nerv Syst. 1998;69(1):21–30. pmid:9672120
  19. 19. Harrington J, Pena AS, Gent R, Hirte C, Couper J. Aortic Intima Media Thickness is an Early Marker of Atherosclerosis in Children with Type 1 Diabetes Mellitus. J Pediatr-Us. 2010;156(2):237–41. pmid:19853860
  20. 20. Heilman K, Zilmer M, Zilmer K, Lintrop M, Kampus P, Kals J, et al. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pr. 2009;84(2):168–73. pmid:19237222
  21. 21. Fazlinezhad A, Rezaeian MK, Yousefzadeh H, Ghaffarzadegan K, Khajedaluee M. Plasma Brain Natriuretic Peptide (BNP) as an Indicator of Left Ventricular Function, Early Outcome and Mechanical Complications after Acute Myocardial Infarction. Clin Med Insights Cardiol. 2011;5:77–83. pmid:21912490
  22. 22. Apple FS, Collinson PO, Biomarkers ITFoCAoC. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54–61. pmid:21965555
  23. 23. Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004;57(10):1025–6. pmid:15452153
  24. 24. Schofield J, Ho J, Soran H. Cardiovascular Risk in Type 1 Diabetes Mellitus. Diabetes Ther. 2019;10(3):773–89. pmid:31004282
  25. 25. Skilton MR, Celermajer DS, Cosmi E, Crispi F, Gidding SS, Raitakari OT, et al. Natural History of Atherosclerosis and Abdominal Aortic Intima-Media Thickness: Rationale, Evidence, and Best Practice for Detection of Atherosclerosis in the Young. J Clin Med. 2019;8(8).
  26. 26. Rosenfeld ME, Averill MM, Bennett BJ, Schwartz SM. Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets. 2008;9(3):210–6. pmid:18336239
  27. 27. Emini Veseli B, Perrotta P, De Meyer GRA, Roth L, Van der Donckt C, Martinet W, et al. Animal models of atherosclerosis. Eur J Pharmacol. 2017;816:3–13. pmid:28483459
  28. 28. Irace C, Casciaro F, Scavelli FB, Oliverio R, Cutruzzola A, Cortese C, et al. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovasc Diabetol. 2018;17(1):52. pmid:29631585
  29. 29. Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J. 2018;65(8):859–67. pmid:29806620
  30. 30. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19(1):110. pmid:32646498
  31. 31. Keles N, Caliskan M, Dogan B, Keles NN, Kalcik M, Aksu F, et al. Low Serum Level of Klotho Is an Early Predictor of Atherosclerosis. Tohoku J Exp Med. 2015;237(1):17–23. pmid:26289053
  32. 32. Saleh S, Hanna G, El-Nabi SH, El-Domiaty H, Shabaan A, Fayez Ewida S. Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model. J Genet. 2020;99. pmid:32529989
  33. 33. Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep. 2018;6(12):e13741. pmid:29932506
  34. 34. Ellmers LJ, Knowles JW, Kim HS, Smithies O, Maeda N, Cameron VA. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol. 2002;283(2):H707–14. pmid:12124219
  35. 35. Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, et al. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. J Am Heart Assoc. 2017;6(6). pmid:28554908
  36. 36. Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, Pereira FC, et al. Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol. 2013;12:44. pmid:23497124
  37. 37. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol. 2004;13(1):11–9. pmid:14761780
  38. 38. Korkmaz-Icoz S, Lehner A, Li S, Vater A, Radovits T, Brune M, et al. Left ventricular pressure-volume measurements and myocardial gene expression profile in type 2 diabetic Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol. 2016;311(4):H958–H71. pmid:27521423
  39. 39. Wang Y, Xu L, Yuan L, Li D, Zhang Y, Zheng R, et al. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes. Diabet Med. 2016;33(12):1732–6. pmid:26927445
  40. 40. Januzzi JL Jr., Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. J Am Coll Cardiol. 2017;70(6):704–12. pmid:28619659
  41. 41. Berezin AE. Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers. Diabetes Metab Syndr. 2019;13(2):995–1003. pmid:31336558
  42. 42. Segre CAW, Hueb W, Garcia RMR, Rezende PC, Favarato D, Strunz CMC, et al. Troponin in diabetic patients with and without chronic coronary artery disease. Bmc Cardiovasc Disor. 2015;15. pmid:26195004
  43. 43. Januzzi JL, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. Journal of the American College of Cardiology. 2017;70(6):704–12. pmid:28619659
  44. 44. Guo Y, Zhuang X, Huang Z, Zou J, Yang D, Hu X, et al. Klotho protects the heart from hyperglycemia-induced injury by inactivating ROS and NF-kappaB-mediated inflammation both in vitro and in vivo. Biochim Biophys Acta Mol Basis Dis. 2018;1864(1):238–51. pmid:28982613
  45. 45. Li X, Li Z, Li B, Zhu X, Lai X. Klotho improves diabetic cardiomyopathy by suppressing the NLRP3 inflammasome pathway. Life Sci. 2019;234:116773. pmid:31422095
  46. 46. Jiang W, Xiao T, Han W, Xiong J, He T, Liu Y, et al. Klotho inhibits PKCalpha/p66SHC-mediated podocyte injury in diabetic nephropathy. Mol Cell Endocrinol. 2019;494:110490. pmid:31207271
  47. 47. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, et al. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc. 2011;59(9):1596–601. pmid:21883107
  48. 48. Nie F, Wu DM, Du HF, Yang XG, Yang M, Pang XL, et al. Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. J Diabetes Complicat. 2017;31(3):594–8. pmid:27916483
  49. 49. Abbas NAT, El Salem A, Awad MM. Empagliflozin, SGLT(2) inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression. N-S Arch Pharmacol. 2018;391(12):1347–60.
  50. 50. McMurray JJV, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endo. 2014;2(10):843–51. pmid:24731668
  51. 51. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2(3):243–9. pmid:8891862
  52. 52. Bozkurt B, Kribbs SB, Clubb FJ Jr., Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97(14):1382–91. pmid:9577950
  53. 53. Oyama J, Shimokawa H, Momii H, Cheng X, Fukuyama N, Arai Y, et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest. 1998;101(10):2207–14. pmid:9593776
  54. 54. Dinh W, Futh R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009;8:58. pmid:19909503
  55. 55. Wen HL, Liang ZS, Zhang R, Yang K. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:50. pmid:23530831
  56. 56. Wu M, Yang Y, Wang M, Zeng F, Li Q, Liu W, et al. Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes. Front Pharmacol. 2018;9:855. pmid:30131697
  57. 57. Aragon-Herrera A, Feijoo-Bandin S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677. pmid:31647926
  58. 58. Nasiri-Ansari N, Dimitriadis GK, Agrogiannis G, Perrea D, Kostakis ID, Kaltsas G, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106. pmid:30049285
  59. 59. Koyani CN, Plastira I, Sourij H, Hallstrom S, Schmidt A, Rainer PP, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020;158:104870. pmid:32434052
  60. 60. Armstrong AC, Ambale-Venkatesh B, Turkbey E, Donekal S, Chamera E, Backlund JY, et al. Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 2017;40(3):405–11. pmid:27986796
  61. 61. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;47(4):693–700. pmid:16487830
  62. 62. Jia GH, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circulation Research. 2018;122(4):624–38. pmid:29449364
  63. 63. Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. pmid:30710997
  64. 64. Takasu T, Takakura S. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sci. 2019;230:19–27. pmid:31125563
  65. 65. Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, et al. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol. 2020;36(4):543–53. pmid:31837891
  66. 66. Hodrea J, Balogh DB, Hosszu A, Lenart L, Besztercei B, Koszegi S, et al. Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney. Am J Physiol Renal Physiol. 2020;318(4):F1017–F29. pmid:32116017